Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Stem Cell Research -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (224)	2/7/2006 6:24:53 AM
From: nigel bates	Respond to of 495

ReNeuron signs manufacturing contract with Angel Biotechnology for its ReN005 stem cell line for Huntington's disease. Guildford, UK, 7 February 2006: ReNeuron Group plc (LSE: RENE.L) today announced that it has signed a manufacturing contract with Angel Biotechnology Holdings plc, the UK biopharmaceutical contract manufacturer. Under the contract, Angel will scale up ReNeuron's ReN005 stem cell line for Huntington's disease, initially producing a master cell bank to Good Manufacturing Practice (GMP) standards. ReNeuron has already generated positive pre-clinical efficacy data with this cell line in a Huntington's disease model, and the ReN005 programme is currently in pre-clinical development. The Company's lead ReN001 cell line for stroke has also been scaled up to GMP standard with another contract manufacturer in the UK. Angel is a member of the consortium, led by ReNeuron, which was awarded a £2.2 million bioprocessing grant by the UK Department of Trade and Industry in January 2005. Angel is the manufacturing partner in this consortium, establishing the capability and technologies to scale up stem cell products to GMP standards for clinical and commercial use. Michael Hunt, Chief Executive Officer of ReNeuron, said: "We are delighted to be working with Angel as our manufacturing partner on the ReN005 Huntington's programme. Angel is an emerging leader in the out-sourced GMP manufacture of cell-based therapies. Their capabilities play well to one of ReNeuron's key competitive strengths: the ability to generate stable and efficacious stem cell lines which are capable of rapid and early scale-up for the clinic and beyond. We look forward to a continuing partnership with Angel both on this contract and with the stem cell bioprocessing consortium." Gordon Sherriff, Chief Operating Officer of Angel, said: "Angel is delighted to have contracted with ReNeuron to provide them with GMP cells for use in subsequent clinical trials. The technical transfer to Angel of ReNeuron's technology has gone extremely well and we look forward to further collaborations in the future. This contract moves Angel to the forefront of stem cell manufacturing and is an endorsement of our MHRA1 licensed GMP facilities in Edinburgh and the skill of the team at Angel. We also look forward to continuing to work with ReNeuron in other directions as part of the stem cell bioprocessing consortium."